230 related articles for article (PubMed ID: 12598081)
1. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II.
Seccia TM; Belloni AS; Kreutz R; Paul M; Nussdorfer GG; Pessina AC; Rossi GP
J Am Coll Cardiol; 2003 Feb; 41(4):666-73. PubMed ID: 12598081
[TBL] [Abstract][Full Text] [Related]
2. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Rossi GP; Sacchetto A; Rizzoni D; Bova S; Porteri E; Mazzocchi G; Belloni AS; Bahcelioglu M; Nussdorfer GG; Pessina AC
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):949-56. PubMed ID: 10764658
[TBL] [Abstract][Full Text] [Related]
3. Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Rossi GP; Cavallin M; Belloni AS; Mazzocchi G; Nussdorfer GG; Pessina AC; Sartore S
Cardiovasc Res; 2002 Jul; 55(1):178-89. PubMed ID: 12062721
[TBL] [Abstract][Full Text] [Related]
4. Effects of irbesartan and bosentan on the blood pressure and adrenal zona glomerulosa function in heterozygous transgenic TGR[mREN2]27 rats.
Andreis PG; Rebuffat P; Neri G; Rossi GP; Nussdorfer GG
Life Sci; 2000 Jun; 67(5):543-7. PubMed ID: 10993119
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis.
Seccia TM; Caroccia B; Gioco F; Piazza M; Buccella V; Guidolin D; Guerzoni E; Montini B; Petrelli L; Pagnin E; Ravarotto V; Belloni AS; Calò LA; Rossi GP
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27444511
[TBL] [Abstract][Full Text] [Related]
6. Role of angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, tubulointerstitial and perivascular fibrosis.
Seccia TM; Maniero C; Belloni AS; Guidolin D; Pothen P; Pessina AC; Rossi GP
J Hypertens; 2008 Oct; 26(10):2022-9. PubMed ID: 18806627
[TBL] [Abstract][Full Text] [Related]
7. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts.
Yamamoto K; Masuyama T; Sakata Y; Mano T; Nishikawa N; Kondo H; Akehi N; Kuzuya T; Miwa T; Hori M
Cardiovasc Res; 2000 Aug; 47(2):274-83. PubMed ID: 10946064
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1.
Park JB; Schiffrin EL
Am J Hypertens; 2002 Feb; 15(2 Pt 1):164-9. PubMed ID: 11863252
[TBL] [Abstract][Full Text] [Related]
9. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
[TBL] [Abstract][Full Text] [Related]
10. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
de Boer RA; Pokharel S; Flesch M; van Kampen DA; Suurmeijer AJ; Boomsma F; van Gilst WH; van Veldhuisen DJ; Pinto YM
J Mol Med (Berl); 2004 Oct; 82(10):678-87. PubMed ID: 15322702
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
[TBL] [Abstract][Full Text] [Related]
12. AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.
Cediel E; de Las Heras N; Sanz-Rosa D; Velasco O; Cachofeiro V; Lahera V
Kidney Int Suppl; 2005 Jan; (93):S3-9. PubMed ID: 15613065
[TBL] [Abstract][Full Text] [Related]
13. Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.
Hara K; Kobayashi N; Nakano S; Mori Y; Tsubokou Y; Matsuoka H
Hypertens Res; 2001 Jan; 24(1):55-64. PubMed ID: 11213031
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release.
Leskinen H; Vuolteenaho O; Ruskoaho H
Circ Res; 1997 Jan; 80(1):114-23. PubMed ID: 8978330
[TBL] [Abstract][Full Text] [Related]
15. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
Nicoletti A; Heudes D; Hinglais N; Appay MD; Philippe M; Sassy-Prigent C; Bariety J; Michel JB
Hypertension; 1995 Jul; 26(1):101-11. PubMed ID: 7607712
[TBL] [Abstract][Full Text] [Related]
16. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
Zhang ZZ; Shang QH; Jin HY; Song B; Oudit GY; Lu L; Zhou T; Xu YL; Gao PJ; Zhu DL; Penninger JM; Zhong JC
J Transl Med; 2013 Sep; 11():229. PubMed ID: 24067190
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension.
Vanourková Z; Kramer HJ; Erbanová M; Bäcker A; Cervenka L; Husková Z; Chábová VC; Tesar V; Dvorák P; Malý J; Vanecková I
Vascul Pharmacol; 2009; 50(5-6):194-9. PubMed ID: 19563737
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
Ambrose J; Pribnow DG; Giraud GD; Perkins KD; Muldoon L; Greenberg BH
J Cardiovasc Pharmacol; 1999 Mar; 33(3):433-9. PubMed ID: 10069680
[TBL] [Abstract][Full Text] [Related]
19. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Mulder P; Richard V; Derumeaux G; Hogie M; Henry JP; Lallemand F; Compagnon P; Macé B; Comoy E; Letac B; Thuillez C
Circulation; 1997 Sep; 96(6):1976-82. PubMed ID: 9323089
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
